ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

Phase 2 Completed 95 enrolled ETOP IBCSG Partners Foundation Roche Pharma AG · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

ETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial with two non-comparative parallel arms of atezolizumab plus bevacizumab with carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab and pemetrexed (Arm B) in patients with stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) harbouring EGFR mutations after failure of standard EGFR tyrosine kinase inhibitors (TKIs).

Timeline

Start: 2020-09-29
Primary completion: 2024-07-22
Completion: 2024-07-22

Publications

Soo RA, Vervita K, Fruh M, Cho BC, Majem M, Rodriguez Abreu D, Ribi K, Callejo A, Moran T, Domine Gomez M, Provencio M, Addeo A, Han JY, Ortega Granados AL, Reck M, Blasco A, Garcia Campelo R, Sala Gonzalez MA, Britschgi C, Roschitzki-Voser H, Ruepp B, Gasca-Ruchti A, Haberecker M, Dafni U, Peters S, Stahel RA; ETOP 15-19 ABC-lung collaborators. A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial. Lung Cancer. 2025 Apr;202:108454. doi: 10.1016/j.lungcan.2025.108454. Epub 2025 Feb 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Atezolizumab	Monoclonal antibody	1200 mg	Intravenous
Comparator	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Comparator	Carboplatin	Small molecule	—	—
Comparator	Paclitaxel	Small molecule	175 mg/m2	—
Comparator	Paclitaxel	Small molecule	200 mg/m2	—
Comparator	Pemetrexed	Small molecule	500 mg/m2	—

Indications

No indication recorded.